arrow
D

Daniel S. Childs

mayo clinic
H指数:15
被引数:1,008

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ten-year outcomes of PET-directed salvage nodal radiotherapy and temporary ADT for N1 and M1a hormone-sensitive prostate cancer

PET指导下的挽救性淋巴结放疗联合临时性ADT治疗N1和M1a激素敏感性前列腺癌的十年结果

2026-09-150
OAAI
PSMA-RECAP: [177Lu]Lu-PSMA-617 retreatment in metastatic castration-resistant prostate cancer

PSMA-RECAP:[177Lu]Lu-PSMA-617重复治疗转移性去势抵抗性前列腺癌

2026-08-310
OA
Real-world outcomes and prognostic determinants of enfortumab vedotin plus pembrolizumab in urothelial carcinoma with squamous divergent differentiation and pure squamous cell carcinoma

恩沃利单抗维得尼单抗联合帕博利珠单抗在鳞状分化异质性分化型尿路上皮癌和纯鳞状细胞癌中的真实世界结局及预后决定因素

2026-08-250
OA
LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

LuRa:Radium-223在转移性去势抵抗性前列腺癌患者中继[177Lu]Lu-PSMA-617后的疗效与安全性

2026-06-010
PRE
Inherited DNA repair variants are associated with clonal hematopoiesis and cardiovascular risk in men with metastatic prostate cancer

携带转移性前列腺癌男性中,遗传性DNA修复变异与克隆性造血和心血管风险相关

2026-05-010
OA
Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancer

锁骨上淋巴结转移的转移性前列腺癌患者立体定向体部放射治疗的结局

2026-04-130
OAAI
PSA Zero Radiographic Disease Progression on PSMA PET/CT

PSA零放射学疾病进展(在PSMA PET/CT上)

Cancers
IF4.4
2026-03-040
OAAI
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

比较性生存分析:激素敏感性转移性前列腺癌按疾病体积和转移时间划分——一项动态网络Meta分析

2025-11-040
PRE
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing

晚期前列腺癌中潜在可操作基因组改变的演变:基于连续循环肿瘤DNA检测的真实世界分析

CANCERS
IF4.4
2025-09-180
OAAI
Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer

[177Lu]Lu-PSMA-617在有和无雄激素受体通路抑制剂联合使用情况下,在转移性去势抵抗性前列腺癌患者中的疗效

2025-08-050
PRE
[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases

[177Lu] Lu-PSMA-617治疗伴有脑部和脑桥部转移的转移性去势抵抗性前列腺癌(mCRPC)

2025-07-210
PRE
Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis

对接受诱导恩沃夫妥单抗和/或免疫检查点抑制剂治疗后进展的尿路上皮癌进行巩固性手术的多中心分析

2025-05-260
PRE
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase Inhibitors

奥氮平用于管理抗血管生成酪氨酸激酶抑制剂所致的副作用

2025-05-030
PRE